NASDAQ$RVMD

REVOLUTION Medicines Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Headline financials

Total Revenue

$7.01M

Previous: $7.58M-7.4%
EPS (adj)

-$0.72

Previous: -$0.78+7.7%
R&D Expenses

$68.9M

No prior period
G&A Expenses

$13.2M

No prior period
Capital Expenditures

-$1.76M

Previous: -$1.89M+6.9%
Free Cash Flow

-$69.9M

Previous: -$59.5M-17.3%
Net Income

-$68.1M

Previous: -$57.6M-18.1%
Operating Income

-$75.2M

Previous: -$57.9M-29.7%
Gross Profit

$300K

Previous: $800K-62.5%
Cash & Equivalents

$427M

Previous: $97.7M+337.4%
Total Assets

$1.07B

Previous: $683M+57.2%
Stock-Based Comp

$9.7M

Previous: $6.64M+46.0%

Revenue & EPS history

Revolution Medicines · Revenue · Quarterly

$7.01M

Q1 2023-7.4%vs Q1 2022
Beat estimate in 3 of 14 quarters(21%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+0.1%

Avg return

Earnings day

+0.2%

Avg return

5 days after

+6.7%

Avg return

30 days after

42%

11 / 26 earnings

Positive

+11.7%

Q3 2020

Best reaction

-11.7%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.6%-2.1%+1.4%
Q4 2025-0.9%-2.7%-10.4%
Q3 2025+3.5%+8.0%+34.2%
Q2 2025-4.7%-3.8%+10.4%
Q1 2025+11.4%+6.1%+9.1%
Q4 2024-3.5%-6.3%-7.8%
Q3 2024+4.1%+6.8%-15.3%
Q2 2024-3.0%-0.7%-3.3%
Q1 2024-3.7%-4.4%+3.8%
Q4 2023+3.0%+0.2%+6.7%
Q3 2023-3.0%-11.1%+8.2%
Q2 2023-0.1%+1.2%+8.3%
Q1 2023+3.5%+6.3%+10.6%
Q4 2022+10.0%+4.6%-11.5%
Q3 2022-4.1%+8.1%+17.8%
Q2 2022+0.5%+4.2%-11.1%
Q1 2022-6.4%-7.8%+15.4%
Q4 2021-6.4%-12.7%+29.1%
Q3 2021-1.7%-2.5%-24.4%
Q2 2021-11.7%-5.6%+9.7%
Q1 2021+7.1%+8.2%+10.7%
Q4 2020-9.2%-1.1%+1.8%
Q3 2020+11.7%+10.7%+17.4%
Q2 2020+6.9%-3.8%+8.3%
Q1 2020-1.3%+0.8%+4.9%
Q4 2019-2.5%+4.2%+49.6%
Q3 2019
Q2 2019
Q1 2019
Q4 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro